Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02664883 · ClinicalTrials.gov registry record
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
A clinical trial of Healthy Subject and Metastatic Renal Cell Cancer, sponsored by University of Southern California.
- Active
- Registry status
- 37
- Enrollment target
- 1
- Study location
NCT02664883: Active study of Healthy Subject and Metastatic Renal Cell Cancer, sponsored by University of Southern California.
NCT02664883 is a study of Healthy Subject and Metastatic Renal Cell Cancer that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 37 participants, below the 246-participant average among 16 other Healthy Subject trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02664883, a study of Healthy Subject and Metastatic Renal Cell Cancer, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to therapy, detect the presence of occult spreading of disease, and identify early return of disease.
Primary Outcome
The change in MDSC level in patients with known metastatic renal cell carcinoma who undergo systemic treatment will be determined. These changes will be compared to the changes in tumor burden as evaluated by CT scan or other imaging modality.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
- OTHER Cytology Specimen Collection Procedure
Study Locations (1)
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-09-08 |
| Est. Completion | 2026-10-29 |
What the registry record for NCT02664883 still lists
NCT02664883 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 246-participant average among 16 other Healthy Subject trials with a reported enrollment target (85% lower).
The record links to 6 conditions, with Healthy Subject appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT02664883 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02664883 about?
NCT02664883 is a clinical study titled "Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer". This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to...
What is the current status of trial NCT02664883?
This trial is currently active not recruiting. The enrollment target is 37 participants. The study started on 2015-09-08. Estimated completion is 2026-10-29.
What conditions does trial NCT02664883 study?
This clinical trial studies the following conditions: Healthy Subject, Metastatic Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Recurrent Renal Cell Carcinoma.
What interventions are being tested in trial NCT02664883?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT02664883?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02664883 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subject
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02664883's enrollment target sits among peer trials
37 13th of 16 higher than 4 of 16 other Healthy Subject trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subject trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
RECRUITING · NA
-
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
RECRUITING
-
Food Frequency Questionnaires in Estimating Food Nutrient Intake in Healthy Young Adults
ACTIVE NOT RECRUITING
-
Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients
ACTIVE NOT RECRUITING · NA
-
Physical Activity in Promoting Smoking Cessation in African Americans
ACTIVE NOT RECRUITING · NA
-
Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI